{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:15Z","timestamp":1740148215471,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["CICPF18016FERN 2018"],"award-info":[{"award-number":["CICPF18016FERN 2018"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The platform\u2019s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up\/conduct metrics since its creation until November 2023 were extracted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies\/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies\/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-024-03445-0","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:01:31Z","timestamp":1712772091000},"page":"2351-2359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Antonio","family":"Juan-Ribelles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Alonso-Saladrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Hladun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Lu\u00eds","family":"Dapena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Lassaletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofelia","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Ram\u00edrez-Villar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Lu\u00eds","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Diaz","family":"de Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"del Mar Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Verd\u00fa-Amor\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Molin\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Toboso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frencisco","family":"Lend\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose G\u00f3mez","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Tall\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Acha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-1670","authenticated-orcid":false,"given":"Lucas","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Fern\u00e1ndez-Teijeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Sociedad Espa\u00f1ola de Hematolog\u00eda y Oncolog\u00eda Pedi\u00e1trica (SEHOP)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta G, Van der Zwan JM, Casali PG, Siesling S, Deitos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493\u2013511. https:\/\/doi.org\/10.1016\/j.ejca.2011.08.008.","journal-title":"Eur J Cancer"},{"key":"3445_CR2","unstructured":"Ca\u00f1ete Nieto A, Pardo Romaguera E, Mu\u00f1oz L\u00f3pez A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, et al. C\u00e1ncer infantil en Espa\u00f1a. Estad\u00edsticas 1980\u20132021. Registro Espa\u00f1ol de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de Val\u00e8ncia; 2022."},{"key":"3445_CR3","first-page":"263","volume-title":"Hematol y Oncol Pedi\u00e1tricas","author":"R Peris-Bonet","year":"2015","unstructured":"Peris-Bonet R. Incidencia y supervivencia del c\u00e1ncer infantil. In: Madero L, Lassaleta A, Sevilla J, editors. Hematol y Oncol Pedi\u00e1tricas. 3rd ed. Madrid: Ergon; 2015. p. 263\u201370.","edition":"3"},{"key":"3445_CR4","unstructured":"Ca\u00f1ete Nieto A, Pardo Romaguera E, Alfonso Comos P, Valero Poveda S, Fern\u00e1ndez F\u00e9rriz A, Porta Cebolla S, et al. C\u00e1ncer infantil en Espa\u00f1a. Estad\u00edsticas 1980\u20132022. Registro Espa\u00f1ol de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de Val\u00e8ncia (Edici\u00f3n preliminar); 2023."},{"issue":"12","key":"3445_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","volume":"23","author":"L Botta","year":"2022","unstructured":"Botta L, Gatta G, Capocaccia R, Stiller C, Ca\u00f1ete A, Dal Maso L, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022;23(12):1525\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(22)00637-4.","journal-title":"Lancet Oncol"},{"key":"3445_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJMoa1510795","volume":"374","author":"GT Armstrong","year":"2016","unstructured":"Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833\u201342.","journal-title":"N Engl J Med"},{"key":"3445_CR7","unstructured":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Oncolog\u00eda Pedi\u00e1tricas (SEHOP). http:\/\/www.sehop.org. Accessed 29 December 2023."},{"key":"3445_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/archdischild-2017-313309","volume":"103","author":"S Nordenmalm","year":"2018","unstructured":"Nordenmalm S, Tomasi P, Pallidis C. More medicines for children: impact of the EU paediatric regulation. Arch Dis Child. 2018;103:557\u201364.","journal-title":"Arch Dis Child"},{"key":"3445_CR9","unstructured":"Real Decreto 1090\/2015, de 4 de diciembre, por el que se regulan los ensayos cl\u00ednicos con medicamentos, los Comit\u00e9s de \u00c9tica de la Investigaci\u00f3n con medicamentos y el Registro Espa\u00f1ol de Estudios Cl\u00ednicos. https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2015-14082-A-2015-14082. 2015. Accessed 29 Dec 2023."},{"key":"3445_CR10","unstructured":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Sarcomas (GEIS). http:\/\/www.grupogeis.org. Accessed 28 December 2023."},{"key":"3445_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ctrv.2010.02.008","volume":"36","author":"CM Zwaan","year":"2010","unstructured":"Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, et al. The role of the \u201cinnovative therapies for children with cancer\u201d (ITCC) European consortium. Cancer Treat Rev. 2010;36:328\u201334.","journal-title":"Cancer Treat Rev"},{"key":"3445_CR12","unstructured":"Innovative Therapies for Children with Cancer (ITCC). https:\/\/www.itcc-consortium.org\/about-itcc.php. Accessed 20 December 2023."},{"issue":"12","key":"3445_CR13","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12094-019-02221-9","volume":"21","author":"F Bautista","year":"2019","unstructured":"Bautista F, Ca\u00f1ete A, Ram\u00edrez-Villar GL, et al. Sociedad Espa\u00f1ola de Hematolog\u00eda y Oncolog\u00eda Pedi\u00e1trica (SEHOP). ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clin Transl Oncol. 2019;21(12):1763\u201370. https:\/\/doi.org\/10.1007\/s12094-019-02221-9. (Epub 2019 Oct 9. PMID: 31598904).","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"3445_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s12094-021-02649-y","volume":"23","author":"A Rubio-San-Sim\u00f3n","year":"2021","unstructured":"Rubio-San-Sim\u00f3n A, Hladun Alvaro R, Juan Ribelles A, et al. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol. 2021;23(12):2489\u201396. https:\/\/doi.org\/10.1007\/s12094-021-02649-y. (Epub 2021 Jun 2 PMID: 34076861).","journal-title":"Clin Transl Oncol"},{"key":"3445_CR15","unstructured":"Sofpromed. http:\/\/www.sofpromed.com. Accessed 20 December 2023."},{"issue":"11","key":"3445_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/neuonc\/noad078","volume":"25","author":"EC Hardin","year":"2023","unstructured":"Hardin EC, Schmid S, Sommerkamp A, et al. LOGGIC core bioclinical data bank: added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro Oncol. 2023;25(11):2087\u201397. https:\/\/doi.org\/10.1093\/neuonc\/noad078. (PMID: 37075810; PMCID: PMC10628936).","journal-title":"Neuro Oncol"},{"key":"3445_CR17","unstructured":"ALLTogether1\u2014a treatment study protocol of the alltogether consortium for children and young adults (0\u201345 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). ClinicalTrials.gov Identifier: NCT04307576. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04307576"},{"issue":"7","key":"3445_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.21568","volume":"6","author":"P Berlanga","year":"2023","unstructured":"Berlanga P, Ndounga-Diakou LA, Aerts I, et al. Measuring safety and outcomes for the use of compassionate and off-label therapies for children, adolescents, and young adults with cancer in the SACHA-France Study. JAMA Netw Open. 2023;6(7): e2321568. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.21568. (PMID: 37399010).","journal-title":"JAMA Netw Open"},{"key":"3445_CR19","unstructured":"Survivorship passport. http:\/\/www.survivorshippassport.org. Accessed 15 December 2023."},{"key":"3445_CR20","unstructured":"PROYECTO BEST Investigaci\u00f3n Cl\u00ednica en Medicamentos. BDMetrics Datos y An\u00e1lisis 33\u00aa Publicaci\u00f3n (30 de Junio de 2023). https:\/\/www.medicamentos-innovadores.org\/sites\/medicamentosinnovadores\/InvestigacionClinicaProyectoBESTHome.html."},{"key":"3445_CR21","unstructured":"https:\/\/healthmedia.blog.gov.uk\/2023\/11\/22\/what-were-doing-to-speed-up-clinical-trials-in-the-uk\/. Accessed 15 Dec 2023."},{"key":"3445_CR22","unstructured":"Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. 2014."},{"key":"3445_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","volume":"15","author":"G Gatta","year":"2014","unstructured":"Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2014a population-based study. Lancet Oncol. 2014;15:35\u201347.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03445-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T09:21:39Z","timestamp":1724059299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03445-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03445-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Juan Ribelles has had a consulting\/advisory role for Alexion and Bayer, has participated in educational activities organized by Eusa Pharma, Abbott, and Alexion, and has received travel expenses by Nestle and Alexion. F. Bautista has been a member of a data monitoring committee (DMC) in a clinical trial sponsored by Sanofi, had a consulting or advisory role for Bayer, Amgen, Roche Genentech, EusaPharma, and Eisai, and received honoraria from Servier for educational events (through his current affiliation). A. Ca\u00f1ete has had an advisory role for Norgine, Bayer, Roche, Eusa-Pharma, SERB, and participated in educational activities organized by Eusa Pharma and Norgine and received travel expenses from Eusa-pharma and Nestl\u00e9. A. Rubio-San Simon has had a advisory role for Eusa Pharma and Sanofi and has received travel expenses by Roche and Eusa Pharma. A. Alonso-Saladrigues (AAS): advisory boards (Novartis). S. Rives reports personal fees, honoraria from Novartis, Servier, Celgene\/ Bristol Myers Squibb, Kite\/ Gilead, and Amgen. Also reports being part of DMSB in clinical trial sponsored by Novartis and of a DMC in a clinical trial sponsored by Autolus. A. Lassaletta has had an advisory role for Jazz, Servier, and Alexion; has received travel expenses by Servier, and has participated in educational activities organized by Alexion. G. Ram\u00edrez-Villar has had an advisory role for Alexion, has received travel expenses by Nestl\u00e9 and has participated in educational activities organized by Alexion. J.L.Fuster was a consultant\/advisory member for Amgen, Jazz Pharmaceuticals, and Novartis, received honoraria from Amgen, Servier, Jazz Pharmaceuticals, Pfizer, and Novartis for speaking at symposia and support from Servier and Jazz Pharmaceuticals for attending symposia. C. Diaz-de-Heredia is a member of study steering committees for clinical trials sponsored by Novartis, had a consulting or advisory role for Novartis, Jazz Pharmaceuticals, Biotest and Vertex, has participated in educational activities organized by Novartis and Jazz Pharmaceuticals and received travel expenses from Jazz Pharmaceuticals and Novartis. J. Verd\u00fa-Amor\u00f3s has received honoraria by Servier and received travel expenses by Servier and EusaPharma. A. Molin\u00e9s has participated in educational activities organized by Servier receiving travel and accommodation expenses. L. Moreno has been member of data monitoring committees for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi and Incyte; had a consulting role for Novartis, Norgine, Boehringer, Ymabs, Bayer, Abbvie, BMS and Shionogi; participated in educational activities organized by Bayer and Eusa Pharma and received travel expenses from Eusa Pharma. He is President Elect of SIOPEN (European neuroblastoma research cooperative group), an organization which receives royalties for the sales of dinutuximab beta. A. Fern\u00e1ndez-Teijeiro has had an advisory role for AstraZeneca, SOBI, Takeda, Norgine, Clinigen, Bayer, Roche, MERCK SHARP & DOHME, Novartis and Takeda; participated in educational activities organized by Amgen, Eusa Pharma, Servier and Takeda and received travel expenses from Servier, Amgen and Gilead. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human studies had been approved by the appropriate ethics committee and had, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Parents and\/or legal guardians of children and adult patients participating in these clinical trials gave their informed consent prior to their inclusion in the studies reported in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}